Prevention of de novo hepatitis B in recipients of core antibody-positive livers with lamivudine and other nucleos(t)ides: A 12-year experience Academic Article uri icon

Overview

MeSH Major

  • Antiviral Agents
  • Donor Selection
  • Hepatitis B
  • Hepatitis B Antibodies
  • Hepatitis B virus
  • Lamivudine
  • Liver Transplantation
  • Tissue Donors

abstract

  • LAM monoprophylaxis was effective in preventing de novo HBV in the vast majority of recipients over long-term follow-up. Adefovir had a higher rate of de novo infections numerically, whereas tenofovir and entecavir had no cases and may be more effective, but this was limited by a small sample size.

publication date

  • April 15, 2013

Research

keywords

  • Academic Article

Identity

Language

  • eng

Digital Object Identifier (DOI)

  • 10.1097/TP.0b013e3182845f97

PubMed ID

  • 23545507

Additional Document Info

start page

  • 960

end page

  • 5

volume

  • 95

number

  • 7